Multiple publications have indicated that FGF23 is a novel biomarker of CV risk; however, most of them have promoted a clear relationship between FGF23 level and CV mortality and morbidity in patients with HF rather than IHD [23,24]. The gene discussed is FGF23; the disease is hydrops fetalis.